Open AccessBrigatinib for anaplastic lymphoma kinase-tyrosine kinase inhibitor naïve anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: an effective but still broken option
Author(s) -
Biagio Ricciuti,
Giuseppe Lamberti,
Fausto Roila,
Giulio Metro
Publication year - 2019
Publication title -
translational lung cancer research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.474
H-Index - 41
eISSN - 2226-4477
pISSN - 2218-6751
DOI - 10.21037/tlcr.2019.04.15
Subject(s) - anaplastic lymphoma kinase , medicine , cancer research , lung cancer , anaplastic large cell lymphoma , tyrosine kinase , alk inhibitor , crizotinib , tyrosine kinase inhibitor , lymphoma , receptor protein tyrosine kinases , kinase , cancer , oncology , pathology , biology , receptor , microbiology and biotechnology , malignant pleural effusion
Rearrangements of the anaplastic lymphoma kinase ( ALK ) gene occur in approximately 5% of non-small cell lung cancers (NSCLCs), in which they identify a distinct subtype of lung tumor that shows exquisite sensitivity to therapy with ALK tyrosine kinase-inhibitors (ALK-TKIs) (1).
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom